---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-026511"
form_type: "8-K"
ticker: "VXRT"
cik: "0000072444"
company_name: "Vaxart, Inc."
filed_at: "2025-08-13T23:59:59+00:00"
generated_at: "2026-05-17T14:04:59.828615+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vaxart Q2 rev $39.7M; norovirus antibodies up 141%; COVID trial stopped at 5K enrolled

## Summary
- Q2 2025 revenue $39.7M (vs $6.4M YoY); net loss $15.0M ($0.07/sh) vs $16.5M ($0.09/sh).
- Positive norovirus Phase 1: second-gen constructs raised GI.1 blockers 141%, GII.4 94% vs first-gen.
- COVID-19 Phase 2b enrollment halted Aug 5 at ~5,000 of planned 10,000; follow-up continues through late 2026.
- Cash $26.3M; runway into Q1 2026; exploring partnerships and non-dilutive funding to extend.
- Special meeting Sep 5 to vote on reverse stock split (1:5 to 1:20) for Nasdaq compliance.

## SEC filing metadata
- accession: 0001437749-25-026511
- form_type: 8-K
- ticker: VXRT
- cik: 0000072444
- company_name: Vaxart, Inc.
- filed_at: 2025-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/72444/000143774925026511/0001437749-25-026511-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/72444/000143774925026511/vxrt20250813_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-026511
- JSON: https://secwatch.observer/filing/0001437749-25-026511.json
- Plain text: https://secwatch.observer/filing/0001437749-25-026511.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.